Navigation Links
Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
Date:6/24/2011

GENEVA, June 24, 2011 /PRNewswire/ -- Selexis SA is a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs. The Company announced today it will be showcasing the new Selexis SUREvariant Screening™ Service by giving away one free SUREvariant Screening at the 2011 BIO International Convention being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.  

Using the Selexis SUREvariant Screening Platform, Selexis will generate high-performance Selexis SUREpools™ for up to 4 monoclonal antibodies or recombinant protein variants, each SUREpool expressing a unique protein of interest.  Selexis will then transfer cell culture supernatants (Selexis SUREnatants™) from each of the Selexis SUREpools to contest winner for use in preclinical testing.

Contestants may enter the contest by dropping off a business card at the Selexis booth 1906 during exhibit hall hours.  There is no purchase necessary to enter the content.  Limit one entry per company.  The winner will be chosen by random ballot on the last day of the conference, Thursday, June 30, 2011.  

As described by industry thought leaders in recent technical conferences, producing preclinical lead proteins in a cGMP production platform can significantly improve preclinical decisions by reducing or eliminating heterogeneity of recombinant protein batches. The heterogeneity is caused by multiple technologies used in protein expression and impact mainly post-translational modifications.

Contest Description:

  • Rapid development of up to four (4) Selexis SUREpools, each expressing a monoclonal antibody or recombinant protein variant of interest
  • Transfer to contest winner Selexis SUREnatant for each Selexis SUREpool
  • Program value of over euro 25,000

Contest Project Scope Includes:

  • Standard DNA cloning into Selexis SUREtech Vectors™
  • Transfection using Selexis SUREfection Procedures™
  • Stable pool selection using Selexis SURE procedures
  • Shipment of Selexis SUREnatants to contest winner

Contest Program Conditions:

  • Contest winner will supply genes of interest in format which can be directly cloned into Selexis SUREtech Vectors
  • Other terms and conditions apply – see a Selexis Business Development representative at the Selexis booth for details
  • No purchase necessary to enter
  • Limit one entry per company

Selexis will be exhibiting in booth number #1906 located in Hall A – Discovery Zone (http://e.mybio.zerista.com/exhibitor/member/17326). For the exhibit hall schedule, visit: http://e.mybio.zerista.com/event/print  

About Selexis SUREvariant Screening™

Selexis' SUREvariant Screening™ accelerates and improves outcomes from displayed library selection campaigns by reducing the time and the number of steps to identify potential lead candidates. The SUREvariant Screening™ platform used at Selexis can generate panels of up to 500 CHO-M cell pools (SUREpools™), each expressing different protein variants. Typical expression levels in the supernatants (SUREnatants™) for MAbs vary between 50-500 mg/L. The SUREnatants™ containing the recombinant proteins expressed with mammalian post-translational modifications can be readily assessed for activity. Subsequently, Selexis SUREpools™ top candidates can be banked (stored) and then reused for further assays. The top SUREpool™ candidate is transferred to the Selexis' SURE Cell Line™ Development platform to generate a high producing clonal cell line ready for cGMP manufacturing. The entire process from SUREvariant Screening™ to the clonal cell line can be as short as 14 weeks. Selexis SUREvariant Screening™ can reduce your development costs by over $500,000 per clinical candidate!

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit selexis.com

Like us on Facebook
Follow us on Twitter

Media Contact: Robert Meister, (602) 953-1716, robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Verizon to Invest $125,000 to Support Domestic Violence Outreach, Prevention, Education and Awareness Programs in Virginia
7. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
8. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
9. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
10. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
11. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2020)... ... 13, 2020 , ... True Terpenes , the leading platform for terpene ... (SAB) to research the medical potential of terpenes and the potential entourage effect ... The board is focused on expanding the recently launched line of effects-based terpenes - ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... that they have entered into a strategic partnership whereby Catalent will provide support ...
Breaking Biology Technology:
(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based in ... into license agreements with Housey Pharma’s HMI subsidiary to gain access to its ... annual Research and Development spending in excess of US $10 billion. , Scientists ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
Breaking Biology News(10 mins):